Delving into the Latest Updates on ACY-257 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

HDAC6

Mechanism

HDAC6 inhibitors(Histone deacetylase 6 inhibitors)

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Inflammation

Originator Organization

Acetylon Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Acetylon Pharmaceuticals, Inc.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

BACKGROUNDHDAC6 is a class IIB histone deacetylase expressed at many levels of the nociceptive pathway. This study tested the ability of novel and selective HDAC6 inhibitors to alleviate sensory hypersensitivity behaviors in mouse models of peripheral nerve injury and peripheral inflammation.METHODSWe utilized the murine spared nerve injury (SNI) model for peripheral nerve injury and the Complete Freund's Adjuvant (CFA) model of peripheral inflammation. We applied the Von Frey assay to monitor mechanical allodynia.RESULTSUsing the SNI model, we demonstrate that daily administration of the brain-penetrant HDAC6 inhibitor, ACY-738, abolishes mechanical allodynia in male and in female mice. Importantly, there is no tolerance to the antiallodynic actions of these compounds as they produce a consistent increase in Von Frey thresholds for several weeks. We observed a similar antiallodynic effect when utilizing the HDAC6 inhibitor, ACY-257, which shows limited brain expression when administered systemically. We also demonstrate that ACY-738 and ACY-257 attenuate mechanical allodynia in the CFA model of peripheral inflammation.CONCLUSIONSOverall, our findings suggest that inhibition of HDAC6 provides a promising therapeutic avenue for the alleviation of mechanical allodynia associated with peripheral nerve injury and peripheral inflammation.

100 Deals associated with ACY-257

Login to view more data